Molbio Diagnostics

Funding rounds

Timeline

• 2021
• May 2021 Series B: $19.2 million from Motilal Oswal The Hindu BusinessLine
• 2022
• Sep 2022 Growth round: $85 million from Temasek and Motilal Oswal Alternates The Hindu BusinessLine
• 2025
• Sep 2025 Reported FY25 revenue of about ₹1,020 crore and profit of ₹138 crore Entrackr
• Dec 2025 SEBI cleared the IPO Entrackr
• 2026
• Aug 2026 Raised ₹281.5 crore from 33 anchor investors Moneycontrol
• Aug 2026 IPO opened on 10 August, price band ₹768 to ₹807 Moneycontrol
• Aug 2026 Listed at ₹980, about 21% above issue price EntrackrNDTV ProfitFinancial Express
• Oct 2026 Motilal Oswal fund sold about 2% for ₹306 crore; HDFC Mutual Fund bought about 2% The Hindu BusinessLine

The short version

• Molbio makes Truenat, a portable machine that runs lab-quality germ tests, such as for TB, away from big labs. The Hindu BusinessLineEntrackr
• It earns from selling the machines and, more so, the test kits used with them. The Hindu BusinessLine
• Buyers include government health programmes, aid agencies, hospitals and labs. The Hindu BusinessLine
• It is based in Verna, Goa, and its subsidiary Bigtec Labs does research. The Hindu BusinessLineEntrackr
• Its revenue was about ₹1,020 crore in FY25, with a profit after tax of ₹138 crore. Entrackr
• SEBI cleared its IPO in December 2025. Entrackr
• It raised ₹281.5 crore from 33 anchor investors on 7 August 2026, before the ₹939.7 crore IPO. MoneycontrolEntrackr
• Shares listed on 17 August 2026 at ₹980, about 21% above the ₹807 issue price. EntrackrNDTV Profit
• In early October 2026 a Motilal Oswal fund sold about 2% of the company for ₹306 crore, and HDFC Mutual Fund bought about 2%. The Hindu BusinessLine

Deals and partnerships

Products

• Truenat: A portable machine that runs lab-grade tests for infectious diseases such as TB. About 30 diseases and 42 tests were on offer at IPO time. The Hindu BusinessLineEntrackr
• Test kits: Single-use kits for the machines. Most revenue comes from TB kits sold to public health programmes. The Hindu BusinessLine
• Other devices: A breast-screening device, a portable X-ray reading tool and digital pathology systems. The Hindu BusinessLine

People

• Sriram Natarajan: Co-founder, executive director and CEO. Leads business strategy, fundraising and government partnerships. The Hindu BusinessLine
• Dr Chandrasekhar Bhaskaran Nair: Co-founder, director and CTO. Directs the chip design and test development behind Truenat. The Hindu BusinessLine

Licences and legal

• Dec 2025 SEBI published its observations, clearing the IPO. Entrackr

Every story on Molbio Diagnostics

• MDMolbio Diagnostics · Stake sale · 1 October 2026 · ₹306 CrMotilal Oswal fund sells 2% of MolbioMolbio Diagnostics is a Goa-based maker of molecular diagnostic tests and devices, now listed on the stock exchanges
• MDMolbio Diagnostics · IPO · 17 August 2026 · Rs 939.7 croreMolbio Diagnostics lists at 21% premium on exchangesMolbio Diagnostics makes point-of-care molecular diagnostic systems for multiple diseases
• MDMolbio Diagnostics · Funding · 7 August 2026 · ₹281.5 CrMolbio raises Rs 281.5 crore from anchorsMolbio Diagnostics allotted 34.87 lakh shares to 33 anchor investors (big funds that commit just before an IPO), raising Rs 281.5 crore
• MDMolbio Diagnostics · IPO · 9 December 2025SEBI clears Molbio Diagnostics for IPOMarket regulator SEBI cleared Molbio Diagnostics to launch its initial public offering, with its observations published in December 2025
• MDMolbio Diagnostics · Results · 1 September 2025Molbio posts Rs 1,020 crore FY25 revenueMolbio Diagnostics reported revenue of about Rs 1,020 crore for FY25, the year ended March 2025